Impact of Oncotype DX recurrence score in the management of breast cancer cases

Clinical Breast Cancer

Volumn 14, Issue 3, 2014, Pages 182-190

  Nguyen, Michaela T ^a   Stessin, Alexander ^a   Nagar, Himanshu ^a   D'Alfonso, Timothy M ^a   Chen, Zhengming ^a   Cigler, Tessa ^a   Hayes, Mary Kay ^a   Shin, Sandra J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant chemotherapy; Intermediate risk score; Multigene assay; Node negative; Node positive

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SIZE; CLINICAL FEATURE; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MICROMETASTASIS; ONCOLOGIST; ONCOTYPE DX RECURRENCE SCORE; PRIMARY TUMOR; RATING SCALE; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; CARCINOMA; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RISK FACTOR; TUMOR RECURRENCE; UTILIZATION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899990581     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.12.002     Document Type: Article

References (19)

1. I. Wolf, N. Ben-Baruch, and R. Shapira-Frommer et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study Cancer 112 2008 731 736
2. S. Paik, S. Shak, and G. Tang et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer J Clin Oncol 23 suppl 16 2005 abstract 510
3. S. Paik, S. Shak, and G. Tang et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
4. S. Paik, G. Tang, and S. Shak et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 2006 3726 3734
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology: Breast Cancer (version 3.2013). http://www.nccn.org/professionals/ physician-gls/pdf/breast.pdf. Accessed May 2, 2013.
6. United States National Institutes of Health. Clinicaltrials.gov [Web site]. Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (the TAILORx trial). Available at: http://clinicaltrials.gov/ct2/show/NCT00310180. Accessed: May 2, 2013.
7. J. Asad, A. Jacobson, and A. Estabrook et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196 2008 527 529
8. R. Goncalves, and R. Bose Using multigene tests to select treatment of early-stage breast cancer J Natl Compr Canc Netw 11 2013 174 182
9. J. Schneider, and D. Khalil Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use Breast Cancer Res Treat 134 2012 1125 1132
10. S. Sahebjam, R. Aloyz, and D. Pilavdzic et al. Ki 67 is a major, but not the sole determinant of Oncotype DX recurrence score Br J Cancer 105 2011 1342 1345
11. F.O. Ademuyiwa, A. Miller, and T. O'Connor et al. The effects of Oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort Breast Cancer Res Treat 126 2011 797 802
12. B.Z. Clark, D.J. Dabbs, and K.L. Cooper et al. Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases Appl Immunohistochem Mol Morphol 21 2012 287 291
13. C. Markopoulos, G. Xepapadakis, and V. Venizelos et al. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions Eur J Surg Oncol 38 2012 413 419
14. K.S. Albain, W.E. Barlow, and S. Shak et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 2010 55 65
15. M. Dowsett, J. Cuzick, and C. Wale et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study J Clin Oncol 28 2010 1829 1834
16. United States National Institutes of Health. Clinicaltrials.gov [Web site]. tamoxifen citrate, letrozole, anastrozole, or exemestane with or without chemotherapy in treating patients with invasive RxPONDER breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01272037. Accessed: May 2, 2013.
17. M. Saghatchian, S. Mook, and G. Pruneri et al. Additional prognostic value of the 70-gene signature (MammaPrint) among breast cancer patients with 4-9 positive lymph nodes Breast 22 2013 682 690
18. United States National Institutes of Health. Clinicaltrials.gov [Web site]. genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes. Available at: http://clinicaltrials.gov/ct2/show/NCT00433589. Accessed: May 2, 2013.
19. M. Martin, A. Prat, and A. Rodriguez-Lescure et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer Breast Cancer Res Treat 138 2013 457 466